AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12918553
Drug: Unwrapped hydroxyapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unwrapped hydroxyapatite implant
Trial: 10945031
Drug: CMF combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF combination therapy
Trial: 1893683
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (Vacusac)
Trial: 1893683
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (Vacusac) after placebo
Trial: 24599532
Drug: Vi capsular
RxNorm normalized name: typhoid vaccine VI capsular polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi capsular polysaccharide typhoid vaccine (25 μg, single dose)
Trial: 21917503
Drug: Saline rinsing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline rinsing of one eye after wearing PureVision™ lenses pre-soaked in ReNu MultiPlus® solution for 1 hour
Trial: 16085692
Drug: PS‐341 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS‐341 1.5 mg/m(2) i.v. bolus on days 1, 4, 8 and 11 (Arm A)
Trial: 16085692
Drug: PS‐341 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS‐341 1.0 mg/m(2) plus gemcitabine 1,000 mg/m(2) i.v. on days 1 and 8 (Arm B)
Trial: 1065757
Drug: Supervised daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised daily toothbrushing and flossing (10 sessions of instruction in plaque removal)
Trial: 1065757
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no instruction in oral hygiene procedures)
Trial: 1065757
Drug: Supervised daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised daily toothbrushing and flossing
Trial: 31738351
Drug: Yogurt group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt group (consumed 112 mL yogurt drink fermented with OLL1073R‐1 daily for 16 weeks)
Trial: 21342748
Drug: Feed supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feed supplement
Trial: 8436090
Drug: Cod liver
RxNorm normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod liver oil (CLO) 25 ml daily for 8 weeks
Trial: 30954948
Drug: Control group;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group; participants followed their regular preparation for the running event.
Trial: 23036264
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment for 3 weeks
Trial: 8683286
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 3 weeks
Trial: 8892450
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and radiation dose or fractionation
Trial: 1734985
Drug: Intensified insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensified insulin treatment and home blood glucose monitoring
Trial: 2429084
Drug: ICI 118,551
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118,551 (20 mg t.i.d.)
Trial: 22441743
Drug: Aclidinium 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium 200 μg
Trial: 22441743
Drug: Aclidinium 400
RxNorm normalized name: aclidinium 400 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium 400 μg
Trial: 18326596
Drug: High rTFA
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High rTFA diet (10.2 g/2500 kcal)
Trial: 18326596
Drug: iTFA diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iTFA diet (10.2 g/2500 kcal)
Trial: 18326596
Drug: Moderate rTFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate rTFA diet (4.2 g/2500 kcal)
Trial: 16436342
Drug: Nadifloxacin 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadifloxacin 1% cream
Trial: 16436342
Drug: Erythromycin 2%
RxNorm normalized name: ERYTHROMYCIN 2% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 2% cream
Trial: 14628252
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion (1, 3, and 10 ng/kg/min for 45 min)
Trial: 14628252
Drug: AT (1)-receptor
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT (1)-receptor antagonist (160 mg valsartan) prior to angiotensin II infusion
Trial: 14628252
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion and AT (1)-antagonist administration
Trial: 8731547
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment for PTSD
Trial: 8731547
Drug: Treatment/wait list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment/wait list comparison group (weekly PTSD outpatient group therapy)
Trial: 29744866
Drug: Dietary counseling
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary counseling and twice‐weekly exercise classes
Trial: 22121129
Drug: golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab 50 mg + MTX (Group 2)
Trial: 21223649
Drug: Pressure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure treatment group (custom pressure garment with 10% strain rate of pressure + 9 mm thick local pressure padding, worn more than 23 hours per day)
Trial: 21223649
Drug: Pressure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure treatment group (5.6 mm Hg pressure)
Trial: 21223649
Drug: Pressure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure treatment group (2.8 and 5.6 mm Hg pressure)
Trial: 16052760
Drug: 35% phosphoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% phosphoric acid (0.5 ml)
Trial: 8849298
Drug: Topical itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical itraconazole
Trial: 8849298
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole (Sporanox)
Trial: 2236467
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of fluphenazine decanoate
Trial: 484261
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for 8 days
Trial: 484261
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for 15 days
Trial: 21684425
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccine (IIV)
Trial: 30759228
Drug: Quadrivalent live‐attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent live‐attenuated influenza vaccine (LAIV)
Trial: 24921418
Drug: Behaviorally oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviorally oriented treatment modality
Trial: 24921418
Drug: Insight oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insight oriented treatment modality
Trial: 18298358
Drug: Individual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual therapy
Trial: 24921418
Drug: Internet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet therapy
Trial: 21628603
Drug: Aclidinium IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium IV doses (25-400 µg)
Trial: 21628603
Drug: Inhaled aclidinium
RxNorm normalized name: aclidinium Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aclidinium (200 µg)
Trial: 15370401
Drug: Topical phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical phenytoin sodium suspension 2%
Trial: 7850531
Drug: Hyperinsulinemic parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic parenteral nutrition (1.44 U/kg/day regular human insulin)
Trial: 29294501
Drug: 17-alpha hydroxyprogesterone
RxNorm normalized name: 17-alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-alpha hydroxyprogesterone caproate (17-OHPC) 250 mg
Trial: 23125943
Drug: Gauze dressing
RxNorm normalized name: Xeroform Petrolatum 1inch 8inch Gauze Dressing (Occlusive)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gauze dressing daily for 7 days
Trial: 23125943
Drug: Transdermal GTN
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal GTN (5 mg/24 hours)
Trial: 20021250
Drug: Topical bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Topical bevacizumab (5 mg/ml) twice a day and betamethasone four times daily for 1 week
Trial: 8907343
Drug: Allopurinol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (10 mg/kg/day during the first week and 15 mg/kg/day thereafter)
Trial: 3321540
Drug: Oral terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline 7.5 mg twice daily
Trial: 23376451
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg tid) plus Behavioral Weight Loss (BWL)
Trial: 21454244
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel alternating between abdomen and upper arms/shoulders
Trial: 17726409
Drug: Single-dose intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intramuscular dexamethasone
Trial: 11878525
Drug: Sitting for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitting for 20 minutes after administration of 3 ml of 0.5% hyperbaric bupivacaine solution
Trial: 10450749
Drug: GM-CSF, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF, 5 microg/kg/day from day 4 to day 8 of EMA chemotherapy
Trial: 10450749
Drug: Placebo from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo from day 4 to day 8 of EMA chemotherapy
Trial: 28068788
Drug: Probiotic preparation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic preparation (containing Lactobacillus helveticus and Bifidobacterium longum)
Trial: 25555154
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for 12 months
Trial: 19474657
Drug: LAC group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC group: lansoprazole 30 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily for 14 days
Trial: 19474657
Drug: BLTM group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLTM group: bismuth subcitrate 300 mg 4 times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg 4 times a day, and metronidazole 500 mg twice daily for 10 days
Trial: 15571316
Drug: Mizolastine 10
RxNorm normalized name: mizolastine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine 10 mg once daily for 14 days
Trial: 2472488
Drug: Subcutaneous interferon-beta
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon-beta serine (IFN‐beta ser)
Trial: 2472488
Drug: Intravenous interferon-beta
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous interferon-beta serine (IFN‐beta ser)
Trial: 2472488
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of interferon-beta serine (180 X 10(6) IU)
Trial: 2472488
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose of interferon-beta serine (45 X 10(6) IU)
Trial: 30579569
Drug: BIKEN varicella-zoster
RxNorm normalized name: varicella/zoster immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIKEN varicella-zoster vaccine (BVZV) with 23-valent polysaccharide pneumococcal vaccine (PPSV23)
Trial: 30579569
Drug: 23-valent polysaccharide
RxNorm normalized name: pneumococcal 23-valent polysaccharide vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent polysaccharide pneumococcal vaccine (PPSV23)
Trial: 21823420
Drug: Bushen Huoxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bushen Huoxue Recipe (BSHXR), one dose per day (taken in two times) for 8 weeks
Trial: 21823420
Drug: Monopril 10
RxNorm normalized name: Monopril 10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monopril 10 mg, once daily for 8 weeks (control group)
Trial: 21823420
Drug: Monopril 10
RxNorm normalized name: Monopril 10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monopril 10 mg, once daily (control group)
Trial: 18465239
Drug: Renzapride (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renzapride (1, 2, or 4 mg/day)
Trial: 15018590
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (IVIg) therapy
Trial: 11168085
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir therapy
Trial: 8325047
Drug: Sulodexide 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide 50 mg enteric-coated tablets twice daily
Trial: 8325047
Drug: Sulodexide 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide 100 mg enteric-coated tablets once daily
Trial: 21166853
Drug: Insulin group
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin group (n=144, 70% of insulin users)
Trial: 21166853
Drug: Insulin group
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin group (n=144)
Trial: 31544802
Drug: Nutritional rehabilitation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional rehabilitation (NR) for 9±2 months with nutritional counselling and oral nutritional supplementation
Trial: 12356214
Drug: Published reports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Published reports of nine additional studies of single-agent MITO therapy for MS
Trial: 12356214
Drug: Single-agent mitoxantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent mitoxantrone (MITO) therapy
Trial: 7148735
Drug: Aspartame plus
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame plus monosodium L-glutamate (34 mg/kg body weight)
Trial: 28248887
Drug: Sevoflurane with
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane with remifentanil 1.5 μg/kg
Trial: 28248887
Drug: Sevoflurane with
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane with remifentanil 2.0 μg/kg
Trial: 20883985
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment for 4 years
Trial: 18726908
Drug: Pramipexole (D2/D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (D2/D3 agonist)
Trial: 17522474
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of US+CT+KUB
Trial: 17522474
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of US+CT
Trial: 17522474
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of KUB+CT
Trial: 12322866
Drug: Individualized homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized homeopathic therapy
Trial: 22152246
Drug: Liposomal albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal albendazole (L-ABZ)
Trial: 22152246
Drug: L-ABZ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ABZ and T-ABZ
Trial: 17118687
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) treatment (200 microg/day for the first month, then 400 microg/day for men and 600 microg/day for women thereafter)
Trial: 14552082
Drug: Lowering dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowering dialysis fluid bicarbonate concentration from 37 mmol/l to 25 mmol/l
Trial: 14552082
Drug: Adjusting dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusting dialysis fluid sodium concentration from 140 mmol/l to 132 mmol/l
Trial: 4073858
Drug: Ceftriaxone (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (80 mg/kg once daily after an initial dose of 100 mg/kg)
Trial: 31033362
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor (ACEI)
Trial: 26988368
Drug: Dorsal penile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsal penile nerve block (DPNB) with saline (tetracaine gel group)
Trial: 26988368
Drug: Dorsal penile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsal penile nerve block (DPNB) with ropivacaine plus tetracaine gel (combination group)
Trial: 18665163
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (G) added to paclitaxel (T) following epirubicin (E) and cyclophosphamide (C)
Trial: 10584133
Drug: 500 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/m2 amifostine intravenously prior to high-dose radioiodine treatment
Trial: 8561761
Drug: Group treatment
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group treatment for hypochondriasis
Trial: 1667511
Drug: Astragalus membranaceus
RxNorm normalized name: Astragalus membranaceus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus membranaceus (AM) intravenous 24 g/d infused into 5% glucose 250 ml
Trial: 26858433
Drug: Arginine vasopressin
RxNorm normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine vasopressin (AVP) administered intranasally
Trial: 20639355
Drug: Metformin (2×500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2×500 mg/day)
Trial: 18520682
Drug: Other antiretroviral
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antiretroviral drugs
Trial: 9932994
Drug: Brimonidine 0.2%
RxNorm normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine 0.2% twice daily (n = 466)
Trial: 9932994
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% twice daily (n = 371)
Trial: 31591826
Drug: Ivabradine on
RxNorm normalized name: Ivabradine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine on top of guideline-directed medical therapy (GDMT)
Trial: 25864745
Drug: FS plus
RxNorm normalized name: MILK THISTLE 6 [hp_X] in 1 mL / HELIANTHEMUM CANADENSE 6 [hp_X] in 1 mL / SOLANUM DULCAMARA TOP 6 [hp_X] in 1 mL / GALIUM APARINE 6 [hp_X] in 1 mL / MAGNESIUM CHLORIDE 6 [hp_X] in 1 mL / SODIUM SULFATE 6 [hp_X] in 1 mL / VISCUM ALBUM FRUITING TOP 6 [hp_X] in 1 mL / HYDROCHLORIC ACID 6 [hp_X] in 1 mL / ESTRONE 8 [hp_X] in 1 mL / SODIUM CHLORIDE 10 [hp_X] in 1 mL / AILANTHUS ALTISSIMA FLOWERING TWIG 12 [hp_X] in 1 mL / BARIUM CHLORIDE DIHYDRATE 12 [hp_X] in 1 mL / CADMIUM 12 [hp_X] in 1 mL / CEANOTHUS AMERICANUS LEAF 12 [hp_X] in 1 mL / ANAMIRTA COCCULUS SEED 12 [hp_X] in 1 mL / IRIDIUM 12 [hp_X] in 1 mL / THUJA OCCIDENTALIS LEAFY TWIG 12 [hp_X] in 1 mL / CINCHONA OFFICINALIS BARK 12 [hp_X] in 1 mL / OYSTER SHELL CALCIUM CARBONATE, CRUDE 12 [hp_X] in 1 mL / CROTALUS DURISSUS TERRIFICUS VENOM 16 [hp_X] in 1 mL ORAL LIQUID [EBV/CFS Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS plus thyroid hormones
Trial: 17895439
Drug: Community occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community occupational therapy (10 sessions over 5 weeks)
Trial: 8874912
Drug: Ondansetron 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.06 mg.kg‐1 i.v.